A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations

BACKGROUND: Afatinib is an epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI) with proven efficacy for treating patients with advanced or metastatic non-small cell lung cancer (NSCLC). Unfortunately, responses are limited by acquired resistance. Because traditional Korean medici...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Si-Yeon, Ha, Su-Jeong, Park, Ji-Hye, Park, So-Jung, Shin, Seong Hoon, Oak, Chulho, Choi, Jun-Yong, Yoon, Seong Woo, Kim, Jung-A, Yoon, Seong Hoon, Son, Ji Woong, Kim, Seung Joon, Yoo, Hwa-Seung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717758/
https://www.ncbi.nlm.nih.gov/pubmed/33285743
http://dx.doi.org/10.1097/MD.0000000000023455

Ejemplares similares

Ejemplares similares